Roche Forms Clinical Research Hub In Singapore To Accelerate Progress In Personalized Medicine
This article was originally published in The Pink Sheet Daily
Executive Summary
Oncology will be the main focus of the research, followed by virology and imaging techniques. Roche anticipates the hub will be operational by the end of the first quarter of 2010
You may also be interested in...
Investing In China: Views From Windhover's PharmAsia Summit
It's common wisdom within the halls of Big Pharma to look East--especially to China--for future revenue growth as increasing regulatory oversight and reimbursement hurdles in the U.S. and Europe create commercial challenges
Roche China R&D Center Chief Scientific Officer Li Chen On Being a Pioneer in China: An Interview With PharmAsia News (Part 2 of 2)
Swiss-headquartered Roche was the first multinational pharmaceutical outfit to establish a research and development center in China, and the company recently set up one of its PharmaPartnering groups in Shanghai. Roche's China CSO Li Chen sat down with PharmAsia News to talk about how the company is approaching R&D in the region and evolving in tandem with the pharma landscape in China. Chen is also a member of the networking organization BayHelix, which links Chinese life sciences executives.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.